Soligenix Inc. Advances in Treating Severe Oral Mucositis with SGX942

Severe oral mucositis (SOM) significantly impacts the quality of life for cancer patients, often leading to hospitalization, the need for opioid pain management, and feeding tube placement. Soligenix Inc. (NASDAQ: SNGX) is addressing this critical unmet need with SGX942, a therapeutic designed to reduce tissue inflammation, promote healing, and support immune response. The company is currently analyzing combined phase 2 and 3 datasets to plan a subsequent phase 3 study. This condition, a painful side effect of cancer therapy with no FDA-approved treatment, affects nearly all patients undergoing head and neck cancer treatments, highlighting the importance of Soligenix's research and development efforts.

Oral mucositis results from chemotherapy or radiation damaging the mouth's mucous membranes, causing painful ulcers, inflammation, and impaired oral function. The phase 3 data for SGX942 has demonstrated significant improvements in both the duration and severity of mucositis, offering hope for a much-needed solution. For more information on Soligenix's progress and updates, visit https://ibn.fm/SNGX.